Anti-T. Cruzi Antibodies and Methods of Use

US 20090203037A1
Filed: 12/23/2008
Published: 08/13/2009
Est. Priority Date: 12/27/2007
Status: Abandoned Application

First Claim

Patent Images

1. An immunodiagnostic reagent comprising one or more antibodies that specifically bind to a diagnostically relevant region of a T. cruzi polypeptide, wherein said one or more antibodies are selected from the group consisting of an antibody specific for T. cruzi polypeptides comprised by FP3, Pep2, FP10 and FRA polypeptides.

View all claims

1 Assignment

Timeline View

Assignment View

0 Petitions

Accused Products

Abstract

The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of Trypanosoma cruzi.

23 Citations

View as Search Results

42 Claims

1. An immunodiagnostic reagent comprising one or more antibodies that specifically bind to a diagnostically relevant region of a T. cruzi polypeptide, wherein said one or more antibodies are selected from the group consisting of an antibody specific for T. cruzi polypeptides comprised by FP3, Pep2, FP10 and FRA polypeptides.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 26, 27, 28, 29, 30, 31, 42)
- - 2. The immunodiagnostic reagent according to claim 1, wherein said immunodiagnostic reagent comprises two or more of said antibodies.
  - 3. The immunodiagnostic reagent according to claim 1, wherein said immunodiagnostic reagent comprises an antibody selected from the group consisting of:
    - an antibody that specifically binds to a diagnostically relevant region of a T. cruzi polypeptide, wherein the T. cruzi polypeptide is FRA and further wherein said antibody has at last one binding constant selected from the group consisting of;
      
      an association rate constant (k_a) between about 7.0×
      
      10⁵M^−
      
      1s^−
      
      1to about 7.0×
      
      10⁶M^−
      
      1s^−
      
      1, an dissociation rate constant (k_d) between about 4.0×
      
      10^−
      
      3s^−
      
      1to about 3.0×
      
      10^−
      
      1s^−
      
      1and an equilibrium dissociation constant (K_D) between about 5.7×
      
      10^−
      
      10M to about 4.3×
      
      10^−
      
      7M;
      
      (b) an antibody that specifically binds to a diagnostically relevant region of a T. cruzi polypeptide, wherein the T. cruzi polypeptide is Pep2 and further wherein said antibody has at least one binding constant selected from the group consisting of;
      
      an association rate constant (k_a) between about 1.0×
      
      10⁶M^−
      
      1s^−
      
      1to about 8.0×
      
      10⁶M^−
      
      1s^−
      
      1;
      
      an dissociation rate constant (k_d) between about 6.0×
      
      10^−
      
      3s^−
      
      1to about 4.0×
      
      10^−
      
      2s^−
      
      1and an equilibrium dissociation constant (K_D) between about 7.5×
      
      10^−
      
      10M to about 4.0×
      
      10^−
      
      8M;
      
      (c) an antibody that specifically binds to a diagnostically relevant region of a T. cruzi polypeptide, wherein the T. cruzi polypeptide is FP10 and further wherein said antibody has at least one binding constant selected from the group consisting of;
      
      (a) an association rate constant (k_a) between about 5.0×
      
      10⁴M^−
      
      1s^−
      
      1to about 3.0×
      
      10⁵M^−
      
      1s^−
      
      1;
      
      (b) an dissociation rate constant (k_d) between about 1.0×
      
      10^−
      
      4s^−
      
      1to about 8.0×
      
      10^−
      
      4s^−
      
      1; and
      
      (c) an equilibrium dissociation constant (K_D) between about 3.3×
      
      10^−
      
      10M to about 1.6×
      
      10^−
      
      8M;
      
      (d) an antibody that specifically binds to a diagnostically relevant region of a T. cruzi polypeptide, wherein the T. cruzi polypeptide is FP3 and further wherein said antibody has at least one binding constant selected from the group consisting of;
      
      an association rate constant (k_a) between about 2.0×
      
      10⁵M^−
      
      1s^−
      
      1to about 6.0×
      
      10⁶M^−
      
      1s^−
      
      1;
      
      an dissociation rate constant (k_d) between about 2.0×
      
      10^−
      
      5s^−
      
      1to about 8.0×
      
      10^−
      
      4s^−
      
      1; and
      
      an equilibrium dissociation constant (K_D) between about 3.3×
      
      10^−
      
      12M to about 4.0×
      
      10^−
      
      9M; and
      
      (e) any combinations of (a)-(d).
  - 4. The immunodiagnostic reagent according to claim 1, wherein said antibody is a chimeric antibody.
  - 5. The immunodiagnostic reagent according to claim 4, wherein said immunodiagnostic reagent comprises a chimeric antibody selected from the group consisting of:
    - (a) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 80% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      2;
      
      (b) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 80% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      4;
      
      (c) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 80% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      6; and
      
      (d) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 80% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      8.
  - 6. The immunodiagnostic reagent according to claim 4, wherein said immunodiagnostic reagent comprises a chimeric antibody selected from the group consisting of:
    - (a) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 90% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      2;
      
      (b) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 90% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      4;
      
      (c) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 90% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      6; and
      
      (d) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 90% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      8.
  - 7. The immunodiagnostic reagent according to claim 4, wherein said immunodiagnostic reagent comprises a chimeric antibody selected from the group consisting of:
    - (a) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 95% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      2;
      
      (b) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 95% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      4;
      
      (c) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 95% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      6; and
      
      (d) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 95% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      8.
  - 8. The immunodiagnostic reagent according to claim 4, wherein said immunodiagnostic reagent comprises a chimeric antibody selected from the group consisting of:
    - (a) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      2;
      
      (b) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      4;
      
      (c) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      6; and
      
      (d) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      8.
  - 9. The immunodiagnostic reagent according to claim 8, wherein said chimeric antibody comprises a V_Hregion selected from the group consisting of:
    - (a) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      10;
      
      (b) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      14;
      
      (c) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      18; and
      
      (d) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      28.
  - 10. The immunodiagnostic reagent according to claim 8, wherein said chimeric antibody comprises a V_Lregion selected from the group consisting of:
    - (a) a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      12;
      
      (b) a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      16; and
      
      (c) a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      20; and
      
      (d) a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      26.
  - 11. The immunodiagnostic reagent according to claim 8, wherein said chimeric antibody comprises both a V_Hregion and V_Lregion selected from the group consisting of:
    - (a) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      10 and a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      12;
      
      (b) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      14 and a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      16;
      
      (c) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      18 and a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      20; and
      
      (d) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      28 and a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      26.
  - 12. The immunodiagnostic reagent of claim 8, wherein said chimeric antibody is substantially identical to the chimeric antibody expressed by a cell line deposited with the American Type Tissue Collection and selected from the group consisting of PTA-8136, PTA-8138, and PTA-8140.
  - 13. The immunodiagnostic reagent of claim 1, wherein said antibody is substantially identical to the antibody expressed by a cell line deposited with the American Type Tissue Collection and selected from the group consisting of PTA-8137, PTA-8139, PTA-8141 and PTA-8142.
  - 14. The immunodiagnostic reagent according to claim 1, wherein said immunodiagnostic reagent is a reagent selected from the group consisting of a detection reagent, a standardization reagent, and a positive control reagent.
  - 26. A method of standardizing a T. cruzi detection assay comprising using the immunodiagnostic reagent according to claim 1 as a sensitivity panel.
  - 27. A method for detecting a T. cruzi antigen comprising the steps of:
    - (a) contacting a test sample suspected of containing a T. cruzi antigen with the immunodiagnostic reagent according to claim 4 under conditions that allow formation of chimeric antibody;
      
      antigen complexes; and
      
      (b) detecting any chimeric antibody;
      
      antigen complexes formed as indicating the presence of said T. cruzi antigen.
  - 28. The method of claim 27, wherein the chimeric antibody comprises a detectable label.
  - 29. The method of claim 27, wherein the antibody:
    - antigen complexes is contacted with a secondary antibody or fragment thereof, wherein the secondary antibody or fragment thereof comprises a detectable label.
  - 30. A method for detecting a T. cruzi antibody comprising the steps of:
    - (a) contacting a test sample suspected of containing a T. cruzi antibody with one or more T. cruzi antigens specific for the T. cruzi antibody under conditions that allow formation of antigen;
      
      antibody complexes; and
      
      (b) detecting any antigen;
      
      antibody complexes formed as indicating the presence of said T. cruzi antigens,wherein the immunodiagnostic reagent according to claim 4 is used in said method as a positive control or standardization reagent.
  - 31. A diagnostic kit for the detection of T. cruzi comprising the immunodiagnostic reagent of claim 1.
  - 42. A method of purifying an antigen comprising a T. cruzi amino acid sequence having at least 70% sequence identity with a T. cruzi amino acid sequence comprised by the amino acid sequences as set forth in SEQ ID NOs.:
    - 1, 3, 5 or 7, comprising;
      
      (a) contacting a sample suspected of containing a T. cruzi polypeptide with the immunodiagnostic reagent according to claim 1 under conditions that allow formation of chimeric antibody;
      
      antigen complexes;
      
      (b) isolating the chimeric antibody;
      
      antigen complexes formed; and
      
      (c) separating the antigen from the antibody.

15. An antibody that specifically binds to a diagnostically relevant region of a T. cruzi polypeptide selected from the group consisting of T. cruzi polypeptides comprised by FP3, Pep2, FP10 and FRA polypeptides.
- View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24)
- - 16. The antibody according to claim 15, wherein said antibody is selected from the group consisting of:
    - an antibody that specifically binds to a diagnostically relevant region of a T. cruzi polypeptide, wherein the T. cruzi polypeptide is FRA and further wherein said antibody has at last one binding constant selected from the group consisting of;
      
      an association rate constant (k_a) between about 7.0×
      
      10⁵M^−
      
      1s^−
      
      1to about 7.0×
      
      10⁶M^−
      
      1s^−
      
      1, an dissociation rate constant (k_d) between about 4.0×
      
      10^−
      
      3s^−
      
      1to about 3.0×
      
      10^−
      
      1s^−
      
      1and an equilibrium dissociation constant (K_D) between about 5.7×
      
      10^−
      
      10M to about 4.3×
      
      10^−
      
      7M;
      
      (b) an antibody that specifically binds to a diagnostically relevant region of a T. cruzi polypeptide, wherein the T. cruzi polypeptide is Pep2 and further wherein said antibody has at least one binding constant selected from the group consisting of;
      
      an association rate constant (k_a) between about 1.0×
      
      10⁶M^−
      
      1s^−
      
      1to about 8.0×
      
      10⁶M^−
      
      1s^−
      
      1;
      
      an dissociation rate constant (k_d) between about 6.0×
      
      10^−
      
      3s^−
      
      1to about 4.0×
      
      10^−
      
      2s^−
      
      1and an equilibrium dissociation constant (K_D) between about 7.5×
      
      10^−
      
      10M to about 4.0×
      
      10^−
      
      8M;
      
      (c) an antibody that specifically binds to a diagnostically relevant region of a T. cruzi polypeptide, wherein the T. cruzi polypeptide is FP10 and further wherein said antibody has at least one binding constant selected from the group consisting of;
      
      (a) an association rate constant (k_a) between about 5.0×
      
      10⁴M^−
      
      1s^−
      
      1to about 3.0×
      
      10⁵M^−
      
      1s^−
      
      1;
      
      (b) an dissociation rate constant (k_d) between about 1.0×
      
      10^−
      
      4s^−
      
      1to about 8.0×
      
      10^−
      
      4s^−
      
      1; and
      
      (c) an equilibrium dissociation constant (K_D) between about 3.3×
      
      10^−
      
      10M to about 1.6×
      
      10^−
      
      8M;
      
      (d) an antibody that specifically binds to a diagnostically relevant region of a T. cruzi polypeptide, wherein the T. cruzi polypeptide is FP3 and further wherein said antibody has at least one binding constant selected from the group consisting of;
      
      an association rate constant (k_a) between about 2.0×
      
      10⁵M^−
      
      1s^−
      
      1to about 6.0×
      
      10⁶M^−
      
      1s^−
      
      1;
      
      an dissociation rate constant (k_d) between about 2.0×
      
      10^−
      
      5s^−
      
      1to about 8.0×
      
      10^−
      
      4s^−
      
      1; and
      
      an equilibrium dissociation constant (K_D) between about 3.3×
      
      10^−
      
      12M to about 4.0×
      
      10^−
      
      9M; and
      
      (e) any combinations of (a)-(d).
  - 17. The antibody of claim 15, wherein the antibody is a chimeric antibody.
  - 18. The chimeric antibody according to claim 17, selected from the group consisting of:
    - (a) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 80% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      2;
      
      (b) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 80% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      4;
      
      (c) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 80% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      6; and
      
      (d) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 80% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      8.
  - 19. The chimeric antibody according to claim 17, selected from the group consisting of:
    - (a) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 90% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      2;
      
      (b) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 90% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      4;
      
      (c) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 90% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      6; and
      
      (d) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 90% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      8.
  - 20. The chimeric antibody according to claim 17, selected from the group consisting of:
    - (a) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 95% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      2;
      
      (b) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 95% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      4;
      
      (c) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 95% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      6; and
      
      (d) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence having at least 95% sequence identity with an amino acid sequence as set forth in SEQ ID NO.;
      
      8.
  - 21. The chimeric antibody of claim 17, wherein said chimeric antibody is one selected from the group consisting of a monoclonal antibody, a humanized antibody, a single-chain Fv antibody, an affinity maturated antibody, a single chain antibody, a single domain antibody, a Fab fragment, a F(ab′
    - ) fragment, a disulfide-linked Fv, and an anti-idiotypic antibody, or fragments thereof.
  - 22. The chimeric antibody of claim 17, wherein the antibody is monoclonal.
  - 23. The chimeric antibody of claim 17, wherein said chimeric antibody is substantially identical to the chimeric antibody expressed by a cell line deposited with the American Type Tissue Collection and selected from the group consisting of PTA-8136, PTA-8138, and PTA-8140.
  - 24. The antibody of claim 15, wherein said antibody is substantially identical to the antibody expressed by a cell line deposited with the American Type Tissue Collection and selected from the group consisting of PTA-8137, PTA-8139, PTA-8141 and PTA-8142.

25. A cell line that expresses a chimeric antibody that specifically binds to a diagnostically relevant region of a T. cruzi polypeptide, wherein said cell line is selected from the group consisting of a cell line deposited with the American Type Tissue Collection and selected from the group consisting of PTA-8136, PTA-8138, and PTA-8140.

32. An isolated polypeptide comprising a portion of a chimeric antibody that specifically binds to a diagnostically relevant region of a T. cruzi polypeptide selected from the group consisting of T. cruzi polypeptides comprised by FP3, Pep2, FP10 and FRA polypeptides.
- View Dependent Claims (33, 34, 35, 36)
- - 33. The isolated polypeptide according to claim 32, wherein said chimeric antibody is selected from the group consisting of:
    - (a) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      2;
      
      (b) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      4;
      
      (c) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      6; and
      
      (d) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      8.
  - 34. The isolated polypeptide according to claim 32, wherein said polypeptide comprises a V_Hregion selected from the group consisting of:
    - (a) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      10;
      
      (b) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      14;
      
      (c) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      18; and
      
      (d) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      28.
  - 35. The isolated polypeptide according to claim 32, wherein said chimeric antibody comprises a V_Lregion selected from the group consisting of:
    - (a) a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      12;
      
      (b) a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      16;
      
      (c) a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      20; and
      
      (d) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      26.
  - 36. The isolated polypeptide according to claim 32, wherein said chimeric antibody comprises both a V_Hregion and V_Lregion selected from the group consisting of:
    - (a) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      10 and a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      12;
      
      (b) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      14 and a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      16;
      
      (c) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      18 and a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      20; and
      
      (d) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      28 and a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      26.

37. An isolated polynucleotide encoding a portion of a chimeric antibody that specifically binds to a diagnostically relevant region of a T. cruzi polypeptide selected from the group consisting of T. cruzi polypeptides comprised by FP3, Pep2, FP10 and FRA polypeptides.
- View Dependent Claims (38, 39, 40, 41)
- - 38. The isolated polynucleotide according to claim 37, wherein said chimeric antibody is selected from the group consisting of:
    - (a) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      2;
      
      (b) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      4;
      
      (c) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      6; and
      
      (d) a chimeric antibody that specifically binds to an epitope comprised by an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      8.
  - 39. The isolated polynucleotide according to claim 37, wherein said polypeptide comprises a V_Hregion selected from the group consisting of:
    - (a) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      10;
      
      (b) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      14;
      
      (c) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      18; and
      
      (d) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      28.
  - 40. The isolated polypeptide according to claim 37, wherein said chimeric antibody comprises a V_Lregion selected from the group consisting of:
    - (a) a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      12;
      
      (b) a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      16;
      
      (c) a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      20; and
      
      (d) a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      26.
  - 41. The isolated polypeptide according to claim 37, wherein said chimeric antibody comprises both a V_Hregion and V_Lregion selected from the group consisting of:
    - (a) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      10 and a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      12;
      
      (b) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      14 and a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      16;
      
      (c) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      18 and a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      20; and
      
      (d) a V_Hregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      28 and a V_Lregion comprising an amino acid sequence substantially identical to the sequence as set forth in SEQ ID NO.;
      
      26;

Specification

Resources

Litigation Campaign Assessment

Current Assignee
Abbott Laboratories Incorporated
Original Assignee
Abbott Laboratories Incorporated
Inventors
Brophy, Susan E., Tyner, Joan D., Tieman, Bryan C., Siegel, Robert W., Tu, Bailin, Ziemann, Robert N., Tyner, Lowell J., Shah, Dinesh O., Hawksworth, David J.

Application Number

US12/342,641
Publication Number

US 20090203037A1
Time in Patent Office

Days
Field of Search
US Class Current

435/7.100
CPC Class Codes

C07K 16/20   from protozoa

C07K 2317/24   containing regions, domains...

C07K 2317/56   variable (Fv) region, i.e. ...

C07K 2317/92   Affinity (KD), association ...

G01N 2333/44   from protozoa

G01N 2469/10   Detection of antigens from ...

G01N 2469/20   Detection of antibodies in ...

G01N 2496/00   Reference solutions for ass...

G01N 33/56905   Protozoa

Y02A 50/30   Against vector-borne diseas...

Anti-T. Cruzi Antibodies and Methods of Use

First Claim

1 Assignment

0 Petitions

Accused Products

Abstract

23 Citations

42 Claims

Specification

Solutions

Use Cases

Quick Links

Anti-T. Cruzi Antibodies and Methods of Use

First Claim

1 Assignment

Subscription Required

Subscription Required

0 Petitions

Subscription Required

Accused Products

Subscription Required

Abstract

23 Citations

42 Claims

Specification

Subscription Required

Solutions

Use Cases

Quick Links